| Name | Title | Contact Details |
|---|
Our roots belong with the Custom Cabinetmaker. We were cabinetmakers for years and identify with the values and qualities of the custom cabinetmaker. When it comes to developing relationships with our customers, our mission is Success for those we work with, as we build those relationships on our core values of Create Win-Wins, Do the Right Thing, and Make it Better. Were fanatical about assembling a great team, who continue to "make it better" with great products and innovative services for the Custom Cabinetmaker, and have been since 1989.
Liverpool Football Club was founded in 1892 and is one of the worlds most historic and famous football clubs. Honours include 19 League Titles, eight FA Cups, ten League Cups, six European Cups, three UEFA Cups, four European Super Cups, 16 Charity Shields, one FIFA Club World Cup, two Womens Super League and one Womens Championship. As a socially responsible club, Liverpool FC is proud of its heritage and plays a proactive role in its communities through its official charity, Liverpool FC Foundation, which helps children and families in Merseyside and beyond, and the Red Neighbours programme, which creates events and experiences specifically aimed at improving the lives of those living in and around the Anfield area (L4, L5 and L6). Liverpool FC is a global brand and works with leading edge commercial partners around the world providing unparalleled commercial opportunities.
AXIS Automation is an industry leading manufacturing company backed by over 35 years of experience and global reach. We provide a wide range of innovative automated decorating and finishing solutions for the baking and snack food industry. Our drive is our customers. Weve worked with over 400 clients, including Fortune 100 and 500 companies around the world, to perfect their product and streamline their process for greater output and less waste. We are committed to providing reliable, accurate, and efficient systems that deliver better quality product at higher production rates and lower cost. PRECISION With our machinery, consistency and quality always come first. When your product comes out just as expected, every time, you waste fewer ingredients and save more money. Our engineers work with the unique requirements of your product to achieve accurate and precise decorating and finishing solutions. FLEXIBILITY When we design our equipment, we keep in mind that giving you more possibilities allows you more control over your product. Thats why we incorporate flexibility of use into all of our machines so that you can manage which ingredients you use, application rates and production volume. INNOVATION Working with AXIS means finding the solution to your unique production requirements and achieving the consistency and accuracy your product demands. Each machine is designed with both functionality and footprint in mind to streamline your process at an economical and eco-friendly price, ensuring you the highest return on investment. The success of our customers is the result of our dedication to the precision, flexibility and innovation of our equipment that is Built to Last and Designed to Deliver.™
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.